Chemomab Therapeutics (CMMB)
(Delayed Data from NSDQ)
$1.00 USD
-0.03 (-2.44%)
Updated Aug 4, 2025 03:59 PM ET
After-Market: $1.01 +0.01 (1.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
Chemomab Therapeutics Ltd. Sponsored ADR's return on equity, or ROE, is -106.70% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.55%. While this shows that CMMB has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CMMB 1.00 -0.03(-2.44%)
Will CMMB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMMB
KURA Stock Rises More Than 15% This Past Week: Here's Why
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
CMMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Other News for CMMB
Chemomab Therapeutics management to meet with Maxim
CMMB: Upcoming Meeting Hosted by Maxim on August 7-8
Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug
Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Chemomab Therapeutics (CMMB)
CMMB Advances Toward Phase 3 with FDA Approval on Key Milestones | CMMB Stock News